CXL-1020

CXL-1020 is a hydroxylamine-based nitroxyl (HNO) donor. CXL-1020 improves cardiac inotropy/lusitropy and Ca2+ cycling in rats with abnormal relaxation. CXL-1020 induces vasorelaxation and improves cardiac function in canine models. CXL-1020 has been used to research systolic heart failure and stable heart failure[1].

Product Specifications

CAS Number

[950834-06-7]

UNSPSC

12352005

Target

Calcium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/cxl-1020.html

Purity

99.0

Solubility

10 mM in DMSO

Smiles

CS(=O)(C1=C(S(=O)(NO)=O)C=CC=C1)=O

Molecular Formula

C7H9NO5S2

Molecular Weight

251.28

References & Citations

[1]Roof SR, et al. CXL-1020, a Novel Nitroxyl (HNO) Prodrug, Is More Effective than Milrinone in Models of Diastolic Dysfunction-A Cardiovascular Therapeutic: An Efficacy and Safety Study in the Rat. Front Physiol. 2017 Nov 10;8:894.|[2]Mengjun Wang, et al. Intravenous Infusion of CXL-1020, a Novel Nitroxyl (HNO) Donor, Improves Left Ventricular Systolic and Diastolic Function in Dogs with Advanced Heart Failure. CARDIOVASCULAR PHARMACOLOGY. VOLUME 15, ISSUE 6, SUPPLEMENT, S73-S74, AUGUST 01, 2009.